New research in The Lancet Infectious Diseases shows that #Ervebo, a licensed #Ebola #vaccine, induces #Tcell responses vs #Bundibugyo #virus in 65% of recipients after one dose. Promising evidence of cross-reactivity, clinical protection still unproven. lnkd.in/p/ebWXJcA9

“ #Ervebo was developed and licensed solely for the #Zairevirus, but it is the only #Ebola #vaccine available in large quantities today. There are no proven #vaccines for #Bundibugyo.” www.theglobeandmail.com/world/articl...

#Congo begins #Ebola #vaccinations for #healthworkers in the #epicenter of the #outbreak . . . #DRC #Ervebo . . . rhinformatics.beehiiv.com/p/congo-begi...

#Ebolafieber: Weniger schwere Krankheitsverläufe durch die Impfung mit einem anderen Ebolavirus-Impfstoff?

Dazu haben wir eine groß angelegte Studie in der Demokratischen Republik Kongo gestartet.

20.000 medizinische Ersthelfende können sich nun freiwillig mit dem Impfstoff #ERVEBO impfen lassen.

📢 About 20,000 #Ervebo shots will be used for a phase 3 trial to see if the vaccine cross-protects against the rare #Ebola species that has torn through the #DRC.

vist.ly/5i32e

💉Approximately 2,000 frontline workers have received a shot of #Ebola vaccine #Ervebo, which is not licensed for the current species causing the outbreak in the #DRC. Read ⬇️

vist.ly/5hz96